The completion of a mega anti-malaria plant in Nigeria, which reported the most cases of the deadly disease globally in 2023, is being partly stalled by a volatile exchange rate, a source familiar with the project told BusinessDay.
The first-of-its-kind $23 million project led by Emzor Pharmaceut
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
